{'fraction_non_alphanumeric': 0.02127659574468085, 'fraction_numerical': 0.01182033096926714, 'mean_word_length': 4.923076923076923, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Effectiveness of the new carbapenem antibiotic, meropenem, in adult patients with mucoviscidosis].

Clinical efficacy of meropenem (meronem, Zeneca), a new carbapenem, was studied in the treatment of 4 adult patients with mucoviscidosis. The drug was administered as intravenous infusions 3 times a day in a daily dose of 60 mg/kg body weight for 10 days. A positive clinical effect was observed in 3 patients and in 1 patient stabilization of the clinical state was recorded. A significant decrease in the titre of the Pseudomonas aeruginosa colonies in 2 patients and that of the P. aeruginosa mucosa colonies in 3 patients was bacteriologically confirmed. Good tolerance and no side effects of meropenem in the doses used were stated. The study showed that meropenem may be recommended for the treatment of adult patients with mucoviscidosis.